The biotech firm achieved record annual revenue and positive adjusted EBITDA for the full year and each quarter.
Champions Oncology reported $59.4M in revenue for fiscal 2026, marking a record annual performance. The company also achieved $1.6M in adjusted EBITDA, meeting its full-year profitability target.
Management highlighted positive adjusted EBITDA in each of the four quarters, a first for the company. The results align with its fiscal 2027 plan, which includes full funding for its Corellia platform.
Shares of CSBR showed limited immediate reaction following the earnings call disclosure.